Source: Eur Respir J 2016; 48: 617-618
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Rubin Lewis J.. The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: a cautionary tale. Eur Respir J 2016; 48: 617-618

Member's Comments

No comment yet.

Related content which might interest you: Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 792-794 Year: 2009 Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 704-705 Year: 2010 Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 Parasympathetic activity in pulmonary arterial hypertension: could a simple measure do the trick? Source: International Congress 2018 – Pulmonary hypertension: right ventricle function, haemodynamics and exercise Year: 2018 Challenging the concept of adding more drugs in pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701527; 10.1183/13993003.01527-2017 Year: 2017 Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021 Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Renin-angiotensin-aldosterone system activation in different vasculature areas in primary pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 1s Year: 2004 Leptin signalling system as a target for pulmonary arterial hypertension therapy Source: Eur Respir J 2015; 45: 1066-1080 Year: 2015 The dopaminergic system in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Sympathetic nervous system activation is an independent prognostic factor of clinical deterioration in pulmonary arterial hypertensive patients Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Pulmonary arterial hypertension or left heart disease with pulmonary hypertension? Toward noninvasive clarity, but time for a new paradigm Source: Eur Respir J 2015; 46: 299-302 Year: 2015 Novel treatment for pulmonary vascular disease: lessons from pathophysiology Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases Year: 2006 Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms Source: Eur Respir Rev, 30 (160) 200284; 10.1183/16000617.0284-2020 Year: 2021 Hepatotoxicity complicating treatment of pulmonary and central nervous system tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 548s Year: 2002 Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready? Source: Eur Respir J 2014; 44: 1404-1407 Year: 2014 Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer? Source: Eur Respir J 2009; 33: 1247-1249 Year: 2009 Is there an obesity paradox in pulmonary arterial hypertension? Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 The revolution of pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 361-363 Year: 2016 Autoimmunity and pulmonary arterial hypertension: The role of leptin Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011